FealtySign in

BAXTER INTERNATIONAL INC

(BAX)

CIK 10456 · SEC filings only

Not gradedDividend record
shown as history
company entity
74 dividend record entries

Dividend record — shown as history, not graded

A declared dividend is a reported fact, not a promise we grade. Here's the record — raises, holds, and cuts — each linked to its source filing.

Dividend record

74 declarations · 14 raised · 56 held · 1 cut · held 3 quarters

  1. HELD$0.0100/shperiod ended 2026-06-30Filing ↗
  2. NOTED$0.0100/shperiod ended 2026-03-31Filing ↗
  3. HELD$0.1700/shperiod ended 2025-09-30Filing ↗
  4. HELD$0.1700/shperiod ended 2025-06-30Filing ↗
  5. CUT$0.1700/shperiod ended 2025-03-31Filing ↗
  6. HELD$0.2900/shperiod ended 2024-09-30Filing ↗
  7. HELD$0.2900/shperiod ended 2024-06-30Filing ↗
  8. HELD$0.2900/shperiod ended 2024-03-31Filing ↗
  9. HELD$0.2900/shperiod ended 2023-11-30Filing ↗
  10. HELD$0.2900/shperiod ended 2023-09-30Filing ↗
  11. HELD$0.2900/shperiod ended 2023-06-30Filing ↗
  12. HELD$0.2900/shperiod ended 2023-03-31Filing ↗
Descriptive dividend record — every entry links to its source filing. Not graded (a declared dividend is a reported fact, not a promise). Full methodology →
Not yet gradedBuyback record
harness minimum not met
company entity
1 resolved promise

Not enough resolved promises to grade

1 of the 4 resolved buyback promises needed to publish a reliability grade. Here's what we're tracking — we never show a grade we can't back with receipts.

Resolved promises

Pro

Full say-do history

Free scorecards show the 12 most recent resolved buyback promises. See the complete multi-year record with Pro.

See Pro →

Credibility timeline

KEPT · Jul 30, 2020
20202020
Timeline as a list
  • Jul 30, 2020KEPTBaxter’s Board of Directors approved a $1.5 billion increase in authorization for the company’s existing share repurchase plan
1 resolved buyback promise · resolver resolver-v3 · score score-v1. Every verdict links to its source filing. Full methodology →
C−Guidance record
grade
company entity
47 resolved promises

Sector median (Industrial Applications and Services): B+ across 28 graded companies

Resolved promises

Pro

Full say-do history

Free scorecards show the 12 most recent resolved guidance promises. See the complete multi-year record with Pro.

See Pro →

Guidance by basis

45 of 92 guidance figures that were graded or dropped for basis could not be graded on the same basis (49%). Guidance marked “not judged” is in neither number.

Guidance typeSaidGradedDroppedOther
Revenue · GAAP1001
Revenue · non-GAAPcannot be graded180126
Revenue · basis not stated6628038
EPS · GAAP3219013
EPS · non-GAAPcannot be graded6303330

Said counts every revenue and EPS guidance figure on record. Dropped counts figures whose period was reported but which have no comparable GAAP actual in SEC XBRL. Other covers open, superseded, withdrawn and otherwise unresolved figures. The coverage note below counts every figure shown but not graded, including figures whose period has not been reported, so it can be larger.

How the site-wide rate is measured

Compare across companies

Guidance shown, not graded (101)

We show what was said — with its source filing — but never score it. The line under each statement says why.

  1. eps guidance fy · Jul 30, 2026
    Adjusted earnings from continuing operations per diluted share: $1.95 to $2.15
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  2. revenue guidance fy · Jul 30, 2026
    Organic sales growth from continuing operations: 2% to 3%
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  3. eps guidance fy · Apr 30, 2026
    Adjusted earnings from continuing operations per diluted share: $1.85 to $2.05
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  4. eps guidance fy · Feb 12, 2026
    Adjusted earnings from continuing operations per diluted share: $1.85 to $2.05
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  5. eps guidance q · Oct 30, 2025
    The company expects adjusted earnings from continuing operations, before special items, of $0.52 to $0.57 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  6. eps guidance fy · Oct 30, 2025
    The company now expects adjusted earnings from continuing operations, before special items, of $2.35 to $2.40 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  7. eps guidance q · Jul 31, 2025
    The company expects adjusted earnings from continuing operations, before special items, of $0.58 to $0.62 per diluted share.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  8. eps guidance fy · Jul 31, 2025
    The company now expects adjusted earnings from continuing operations, before special items, of $2.42 to $2.52 per diluted share.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  9. revenue guidance q · May 1, 2025
    The company expects sales growth from continuing operations of 4% to 5% on a reported basis and 1% to 2% on an operational basis.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  10. eps guidance fy · May 1, 2025
    The company now expects adjusted earnings from continuing operations, before special items, of $2.47 to $2.55 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  11. eps guidance q · May 1, 2025
    The company expects adjusted earnings from continuing operations, before special items, of $0.59 to $0.63 per diluted share.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  12. revenue guidance fy · May 1, 2025
    Baxter now expects sales growth from continuing operations of 7% to 8% on a reported basis.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  13. eps guidance q · Feb 20, 2025
    The company expects adjusted earnings from continuing operations, before special items, of $0.47 to $0.50 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  14. eps guidance fy · Feb 20, 2025
    expects adjusted earnings from continuing operations, before special items, of $2.45 to $2.55 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  15. revenue guidance fy · Feb 3, 2025
    The company remains committed to its previously announced 2025 financial objectives of 4% to 5% operational sales growth
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  16. revenue guidance q · Nov 8, 2024
    The company expects sales to decline low single digits on both a reported basis and constant currency basis.
    Not judged — the company guided on a basis or for a measure that the reported figure we hold does not match.Filing ↗
  17. revenue guidance fy · Nov 8, 2024
    Baxter now expects total company sales growth of 1% to 2% on a reported basis
    Not judged — the company guided on a basis or for a measure that the reported figure we hold does not match.Filing ↗
  18. eps guidance q · Nov 8, 2024
    The company expects total adjusted earnings, before special items, of $0.77 to $0.81 per diluted share.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  19. eps guidance fy · Nov 8, 2024
    The company expects total company adjusted earnings, before special items, of $2.90 to $2.94 per diluted share.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  20. eps guidance fy · Aug 6, 2024
    The company expects adjusted earnings, before special items, of $2.93 to $3.01 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  21. revenue guidance q · Aug 6, 2024
    and 4% to 5% on a constant currency basis
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  22. eps guidance q · Aug 6, 2024
    The company expects adjusted earnings, before special items, of $0.77 to $0.79 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  23. revenue guidance fy · Aug 6, 2024
    Baxter now expects sales growth of approximately 3% on both a reported and constant currency basis
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  24. eps guidance q · May 2, 2024
    The company expects adjusted earnings, before special items, of $0.65 to $0.67 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  25. revenue guidance q · May 2, 2024
    The company expects sales growth of approximately 1% on a reported basis and 2% to 3% on a constant currency basis
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  26. revenue guidance fy · May 2, 2024
    Baxter now expects sales growth of approximately 2% on a reported basis and 2% to 3% on a constant currency basis
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  27. eps guidance fy · May 2, 2024
    The company expects adjusted earnings, before special items, of $2.88 to $2.98 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  28. eps guidance q · Feb 8, 2024
    The company expects adjusted earnings, before special items, of $0.59 to $0.62 per diluted share.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  29. eps guidance fy · Feb 8, 2024
    The company expects adjusted earnings, before special items, of $2.85 to $2.95 per diluted share.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  30. revenue guidance q · Feb 8, 2024
    The company expects sales growth of approximately 1% on a reported basis and 1% to 2% on a constant currency basis.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  31. revenue guidance fy · Feb 8, 2024
    Baxter expects sales growth of approximately 2% on both a reported and constant currency basis.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  32. eps guidance fy · Nov 2, 2023
    The company expects adjusted earnings from continuing operations, before special items, of $2.57 to $2.60 per share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  33. eps guidance q · Nov 2, 2023
    The company expects adjusted earnings from continuing operations, before special items, of $0.85 to $0.88 per share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  34. eps guidance q · Jul 27, 2023
    The company expects third-quarter adjusted earnings in aggregate (including discontinued operations) of $0.78 to $0.80 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  35. eps guidance fy · Jul 27, 2023
    Baxter expects full-year 2023 adjusted earnings of $2.87 to $2.95 per diluted share in the aggregate (including discontinued operations)
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  36. eps guidance fy · Apr 27, 2023
    adjusted EPS of $2.85 to $3.00
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  37. eps guidance q · Apr 27, 2023
    adjusted earnings, before special items, of $0.59 to $0.61 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  38. eps guidance q · Feb 9, 2023
    adjusted earnings, before special items, of $0.46 to $0.50 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  39. eps guidance fy · Feb 9, 2023
    adjusted earnings, before special items, of $2.75 to $2.95 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  40. eps guidance q · Oct 27, 2022
    adjusted earnings, before special items, of $0.92 to $0.99 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  41. eps guidance fy · Oct 27, 2022
    adjusted earnings, before special items, of $3.53 to $3.60 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  42. eps guidance fy · Jul 28, 2022
    adjusted EPS of $3.60 to $3.70
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  43. eps guidance q · Jul 28, 2022
    adjusted earnings, before special items, of $0.79 to $0.83 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  44. revenue guidance fy · Jul 28, 2022
    2% to 3% on an operational basis
    Not judged — the company guided on a basis or for a measure that the reported figure we hold does not match.Filing ↗
  45. revenue guidance q · Jul 28, 2022
    mid-20s sales growth on a constant currency basis
    Not judged — the company guided on a basis or for a measure that the reported figure we hold does not match.Filing ↗
  46. eps guidance q · Apr 28, 2022
    adjusted earnings, before special items, of $0.86 to $0.89 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  47. eps guidance fy · Apr 28, 2022
    adjusted EPS of $4.12 to $4.20
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  48. eps guidance q · Feb 17, 2022
    adjusted earnings, before special items, of $0.79 to $0.82 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  49. eps guidance fy · Feb 17, 2022
    adjusted earnings, before special items, of $4.25 to $4.35 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  50. eps guidance fy · Oct 28, 2021
    adjusted EPS of $3.58 to $3.62
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  51. eps guidance q · Oct 28, 2021
    adjusted earnings, before special items, of $1.00 to $1.04 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  52. eps guidance q · Jul 29, 2021
    adjusted earnings, before special items, of $0.93 to $0.95 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  53. eps guidance fy · Jul 29, 2021
    adjusted EPS of $3.49 to $3.55
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  54. revenue guidance q · Apr 29, 2021
    The company expects sales growth of 14% to 15% on a reported basis, 8% to 9% on a constant currency basis and 7% to 8% on an operational basis.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  55. revenue guidance fy · Apr 29, 2021
    The company expects sales growth of 8% to 9% on a reported basis, 5% to 6% on a constant currency basis and 4% to 5% on an operational basis.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  56. eps guidance q · Apr 29, 2021
    adjusted earnings, before special items, of $0.72 to $0.75 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  57. eps guidance q · Feb 4, 2021
    adjusted earnings, before special items, of $0.63 to $0.65 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  58. eps guidance fy · Feb 4, 2021
    adjusted earnings, before special items, of $3.35 to $3.43 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  59. revenue guidance fy · Feb 4, 2021
    4% to 5% on a constant currency basis
    Not judged — the company guided on a basis or for a measure that the reported figure we hold does not match.Filing ↗
  60. eps guidance fy · Oct 29, 2020
    adjusted EPS of $3.02 to $3.05
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  61. revenue guidance fy · Oct 29, 2020
    Baxter expects full-year 2020 low single digit sales growth on a reported, constant currency and operational basis
    Not judged — the company guided on a basis or for a measure that the reported figure we hold does not match.Filing ↗
  62. eps guidance fy · Jul 30, 2020
    adjusted EPS of $3.00 to $3.10
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  63. revenue guidance fy · Jul 30, 2020
    Baxter expects full-year 2020 reported sales growth between -1% to +1%
    Not judged — the company guided on a basis or for a measure that the reported figure we hold does not match.Filing ↗
  64. eps guidance q · Mar 17, 2020
    The company expects adjusted net income, before special items, of $0.72 to $0.74 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  65. revenue guidance q · Mar 17, 2020
    and 5% to 6% on both a constant currency and operational basis
    Not judged — the company guided on a basis or for a measure that the reported figure we hold does not match.Filing ↗
  66. revenue guidance fy · Jan 13, 2020
    Baxter expects full-year 2020 sales growth of 4%-5% on both a reported and constant currency basis
    Not judged — the company guided on a basis or for a measure that the reported figure we hold does not match.Filing ↗
  67. revenue guidance q · Oct 24, 2019
    approximately 5% on both a constant currency and operational basis
    Not judged — the company guided on a basis or for a measure that the reported figure we hold does not match.Filing ↗
  68. eps guidance fy · Jul 25, 2019
    adjusted earnings from continuing operations, before special items, of $3.34 to $3.40 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  69. eps guidance q · Jul 25, 2019
    adjusted earnings from continuing operations, before special items, of $0.82 to $0.84 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  70. eps guidance q · Jan 31, 2019
    The company expects adjusted earnings from continuing operations, before special items, of $0.66 to $0.68 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  71. revenue guidance fy · Jan 31, 2019
    and 3 to 4 percent on an operational basis
    Not judged — the company guided on a basis or for a measure that the reported figure we hold does not match.Filing ↗
  72. revenue guidance q · Jan 31, 2019
    to increase approximately 1 percent on a constant currency basis
    Not judged — the company guided on a basis or for a measure that the reported figure we hold does not match.Filing ↗
  73. eps guidance fy · Jan 31, 2019
    The company expects adjusted earnings from continuing operations, before special items, of $3.22 to $3.30 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  74. revenue guidance fy · Jan 31, 2019
    2 to 3 percent on a constant currency basis
    Not judged — the company guided on a basis or for a measure that the reported figure we hold does not match.Filing ↗
  75. revenue guidance q · Jul 26, 2018
    The company expects sales growth of approximately 3 percent on a reported basis
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  76. eps guidance fy · Jul 26, 2018
    The company now expects adjusted earnings from continuing operations, before special items, of $2.94 to $3.00 per diluted share for the full year
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  77. revenue guidance fy · Jul 26, 2018
    The company continues to expect sales growth of approximately 5 percent on a constant currency basis
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  78. eps guidance q · Jul 26, 2018
    The company expects adjusted earnings from continuing operations, before special items, of $0.72 to $0.74 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  79. revenue guidance fy · Jul 26, 2018
    4 to 5 percent on an operational basis
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  80. revenue guidance fy · Jul 26, 2018
    The company now expects sales growth of approximately 6 percent on a reported basis
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  81. eps guidance fy · Apr 26, 2018
    Baxter expects adjusted earnings from continuing operations, before special items, of $2.85 to $2.93 per diluted share for the full year
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  82. eps guidance q · Apr 26, 2018
    The company expects adjusted earnings from continuing operations, before special items, of $0.69 to $0.71 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  83. revenue guidance fy · Apr 26, 2018
    The company now expects sales growth of approximately 7 to 8 percent on a reported basis
    Not judged — the company guided on a basis or for a measure that the reported figure we hold does not match.Filing ↗
  84. eps guidance q · Oct 25, 2017
    The company expects earnings from continuing operations, before special items, of $0.56 to $0.59 per diluted share.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  85. eps guidance fy · Oct 25, 2017
    Earnings from continuing operations, before special items, are now expected to be $2.40 to $2.43 per diluted share.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  86. revenue guidance q · Apr 26, 2017
    Baxter expects underlying constant currency sales growth of approximately 3 percent
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  87. eps guidance fy · Apr 26, 2017
    earnings from continuing operations, before special items, of $2.20 to $2.28 per diluted share for the full year
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  88. revenue guidance fy · Apr 26, 2017
    Baxter expects underlying constant currency sales growth of approximately 4 to 5 percent
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  89. revenue guidance q · Apr 26, 2017
    or approximately 2 percent on a constant currency basis
    Not judged — the company guided on a basis or for a measure that the reported figure we hold does not match.Filing ↗
  90. eps guidance q · Apr 26, 2017
    The company expects earnings from continuing operations, before special items, of $0.55 to $0.57 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  91. eps guidance q · Oct 25, 2016
    Baxter expects earnings from continuing operations, before special items, of $0.49 to $0.52 per diluted share for the fourth quarter of 2016
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  92. eps guidance fy · Oct 25, 2016
    earnings from continuing operations, before special items, of $1.88 to $1.91 per diluted share for the full year
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  93. eps guidance q · Apr 26, 2016
    Baxter expects earnings from continuing operations, before special items, of $0.38 to $0.40 per diluted share for the second quarter of 2016
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  94. revenue guidance q · Apr 26, 2016
    the company expects constant currency sales growth of approximately 4 percent
    Not judged — the company guided on a basis or for a measure that the reported figure we hold does not match.Filing ↗
  95. eps guidance fy · Apr 26, 2016
    the company now expects earnings from continuing operations, before special items, of $1.59 to $1.67 per diluted share for the full year
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  96. revenue guidance fy · Apr 26, 2016
    Baxter now expects constant currency growth for full-year 2016 of approximately 3 percent
    Not judged — the company guided on a basis or for a measure that the reported figure we hold does not match.Filing ↗
  97. revenue guidance q · Oct 27, 2015
    Baxter expects sales growth of 1 to 2 percent in the fourth quarter of 2015
    Not judged — the company gave more than one figure for this period on the same day, and we cannot tell which one the reported figure should be compared with.Filing ↗
  98. eps guidance q · Oct 27, 2015
    Baxter also expects earnings from continuing operations, before special items, of $0.30 to $0.32 per diluted share for the fourth quarter
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  99. revenue guidance fy · Oct 27, 2015
    Baxter expects sales to increase approximately 1 percent excluding the impact of foreign exchange
    Not judged — the company guided on a basis or for a measure that the reported figure we hold does not match.Filing ↗
  100. revenue guidance q · Oct 27, 2015
    the company expects sales to decline approximately 9 percent
    Not judged — the company gave more than one figure for this period on the same day, and we cannot tell which one the reported figure should be compared with.Filing ↗
  101. eps guidance fy · Oct 27, 2015
    for the second half of 2015, the company now expects earnings from continuing operations, before special items, of $0.71 to $0.73 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗

Open promises (7) · 23 superseded

Open · eps guidance q

GAAP earnings from continuing operations for the fourth quarter and second half of $0.23 to $0.25

unresolved — no outcome on filereceipt (opens in a new tab)
Open · eps guidance q

GAAP earnings of $0.36 to $0.39 per diluted share for the fourth quarter of 2016

unresolved — no outcome on filereceipt (opens in a new tab)
Open · eps guidance q

The company expects U.S. GAAP earnings of $0.75 to $0.79 per diluted share

unresolved — no outcome on filereceipt (opens in a new tab)
Open · revenue guidance q

The company expects sales growth of mid-to-high single digits on a reported basis

unresolved — no outcome on filereceipt (opens in a new tab)
Open · eps guidance q

The company expects U.S. GAAP earnings of $0.60 to $0.67 per diluted share

unresolved — no outcome on filereceipt (opens in a new tab)
Open · revenue guidance fy

Reported sales growth from continuing operations: 3% to 4%

resolves in ~155 daysreceipt (opens in a new tab)
Open · revenue guidance fy

Reported sales growth from continuing operations: flat to 1%

resolves in ~155 daysreceipt (opens in a new tab)
Superseded · revenue guidance fy

Baxter now expects sales growth from continuing operations of 6% to 7% on a reported basis.

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Baxter now expects sales to increase approximately 1 percent

revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy

The company expects U.S. GAAP earnings of $2.91 to $2.99 per diluted share

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Baxter expects full-year 2022 sales growth of 23% to 24% on a reported basis

revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy

$8.94 to $9.06 per diluted share for full-year 2016

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

or approximately 4 percent after adjusting for increased U.S. competition for cyclophosphamide

revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy

Baxter now expects full-year U.S. GAAP EPS of $2.82 to $2.88

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Baxter expects sales growth of 7% to 8% on a reported basis

revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy

Baxter now expects full-year U.S. GAAP EPS of $1.82 to $1.92

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Baxter expects sales growth of 1% to 2% on a reported basis

revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy

Baxter expects full-year U.S. GAAP EPS of $2.35 to $2.43

revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy

Baxter now expects U.S. GAAP earnings of $2.85 to $2.93 per diluted share

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Baxter expects sales growth of 24% to 25% on a reported basis

revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy

The company expects U.S. GAAP earnings of $1.43 to $1.63 per diluted share

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Reported sales growth from continuing operations: flat to 1%

revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy

Baxter expects full-year U.S. GAAP EPS of $2.40 to $2.50

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Baxter expects sales growth from continuing operations of 5% to 6% on a reported basis

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

The company now expects sales growth of approximately 1 to 2 percent on a reported basis

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Baxter expects sales growth of 0 to 1 percent on a reported basis

revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy

The company expects U.S. GAAP earnings of $2.91 to $3.01 per diluted share

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Baxter expects full-year 2023 sales growth from continuing operations of 1% to 2% on a reported basis and approximately 2% on a constant currency basis.

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

The company expects sales growth of approximately 8% on a reported basis, 5% to 6% on a constant currency basis and 4% to 5% on an operational basis.

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Baxter expects full-year 2023 sales growth of 1% to 2% on a reported basis

revised by a later guidancereceipt (opens in a new tab)

Credibility timeline

BELOW · Feb 9, 2023UNRESOLVABLE · Apr 27, 2023ABOVE · Apr 27, 2023BELOW · Apr 27, 2023BELOW · Jul 27, 2023IN LINE · Nov 2, 2023ABOVE · Feb 8, 2024ABOVE · Feb 8, 2024ABOVE · Feb 8, 2024UNRESOLVABLE · Aug 6, 2024ABOVE · May 6, 2025BELOW · Nov 4, 2025ABOVE · Feb 12, 2026ABOVE · Feb 12, 2026
20232026
Timeline as a list
  • Feb 9, 2023BELOWBaxter now expects U.S. GAAP earnings (loss) of ($4.52) to ($4.45) per diluted share
  • Apr 27, 2023UNRESOLVABLEThe company expects sales growth of approximately 1% to 2% on a reported basis
  • Apr 27, 2023ABOVEThe company expects sales to decline approximately 3% on a reported basis
  • Apr 27, 2023BELOWThe company expects U.S. GAAP earnings of $0.14 to $0.18 per diluted share
  • Jul 27, 2023BELOWThe company expects U.S. GAAP earnings of $0.18 to $0.20 per diluted share
  • Nov 2, 2023IN LINEThe company expects third-quarter sales growth from continuing operations of approximately 2% on a reported basis and 1% on a constant currency basis.
  • Feb 8, 2024ABOVEThe company expects sales growth from continuing operations of 1% to 2% on a reported basis
  • Feb 8, 2024ABOVEBaxter expects sales growth from continuing operations of 1% to 2% on a reported basis
  • Feb 8, 2024ABOVEBaxter expects full-year U.S. GAAP EPS of $1.16 to $1.31
  • Aug 6, 2024UNRESOLVABLEThe company expects sales growth of 3% to 4% on a reported basis
  • May 6, 2025ABOVEThe company expects sales growth from continuing operations of 3% to 4% on a reported basis
  • Nov 4, 2025BELOWThe company expects sales growth from continuing operations of 6% to 7% on a reported basis
  • Feb 12, 2026ABOVEBaxter now expects sales growth from continuing operations of 4% to 5% on a reported basis
  • Feb 12, 2026ABOVEThe company expects sales growth from continuing operations of approximately 2% on a reported basis and a decline of approximately 2% on an operational basis
47 resolved guidance promises · 103 not graded (no comparable reported figure) · resolver resolver-v5 · score score-v1. Every verdict links to its source filing. Full methodology →